Your session is about to expire
← Back to Search
Cancer Vaccine
VP301 (Dose Escalation) for Lymphoma
Phase 1
Waitlist Available
Research Sponsored by Virtuoso BINco, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 30 months
Awards & highlights
No Placebo-Only Group
Summary
This trial tests a new drug, VP301, in patients whose cancers have returned or did not respond to previous treatments. It aims to find the safest and most effective dose by adjusting the amount given over time.
Eligible Conditions
- Lymphoma
- Multiple Myeloma
- Solid Tumors
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ through study completion, an average of 30 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 30 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Occurrence of Dose Limiting Toxicity
Occurrence of General Toxicity
Secondary study objectives
Antidrug and neutralizing antibodies
Best response
Objective response
+3 moreOther study objectives
Immunoglobulins
Tumor expression
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: VP301 (Dose Expansion)Experimental Treatment1 Intervention
Eligible patients will receive VP301 administered as an IV infusion weekly for 6 weeks then every 2 weeks. Patients will receive the maximum tolerated dose or recommended phase 2 dose during the Dose Expansion period of the study.
Group II: VP301 (Dose Escalation)Experimental Treatment1 Intervention
Eligible patients will receive VP301 administered as an IV infusion weekly for 6 weeks then every 2 weeks. Patients will be enrolled into escalating dose levels during the Dose Escalation period of the study.
Find a Location
Who is running the clinical trial?
Virtuoso BINco, Inc.Lead Sponsor
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have a heart condition that is serious.You are pregnant or breastfeeding.You are experiencing severe symptoms and complications from the spread of cancer to different parts of your body that may be life-threatening.You have already tried all the available treatments for your condition and they did not work, or those treatments are not recommended for you.You have another cancer that could make it difficult to understand the results of this study.
Research Study Groups:
This trial has the following groups:- Group 1: VP301 (Dose Escalation)
- Group 2: VP301 (Dose Expansion)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Learn More About These Treatments
Share this study with friends
Copy Link
Messenger